Chronic Renal Failure (CRF), Graft Failure, Renal Transplant Rejection, Transplant; Failure, Kidney
Conditions
Keywords
kidney transplantation, chronic renal failure, immunosuppressive therapy, elderly, pharmacokinetic, tacrolimus, everolimus, mycophenolate sodium, serious adverse events, biopsy, Cystatin C, metabolic effects, Left Ventricular Mass (LVM), Left Ventricle Ejection Fraction
Brief summary
An exploratory study of the efficacy and safety of a regimen consisted of Everolimus plus low tacrolimus for the immunosuppression in renal transplantation in the elderly. To evaluate the pharmacokinetics of immunosuppressants that have been little studied in this population. To evaluate whether the polymorphism of the genes that determine the expression of metabolizing enzymes and transporters of xenobiotics interfere in the elderly, also in the younger population, absorption and metabolism of immunosuppressants. To evaluate the potential minimization of immunosuppression in this population refers to how does the re-population of peripheral lymphocytes, in this age group, after the use of lymphocyte-depleting agents such as thymoglobulin and subsequently maintained with two regimes. Clarify which markers of renal filtration exist today, cystatin C and serum creatinine, is the right to monitor renal function in elderly transplanted.
Detailed description
Objectives: The objective of this study is to evaluate the safety and efficacy of everolimus (EVL) combined with low dose of Tacrolimus in comparison with Mycophenolate Sodium (MPS) combined with standard dose of Tacrolimus as immunosuppressive therapy for elderly recipients of kidney transplantation. Comparison between the two study arms of: Primary Objective: 1\. Composite efficacy failure demonstrated by graft loss and/or death with functional graft and/or GFR (Glomerular Filtration Rate determined by EDTA-Cr51) \< 50 ml/min at the end of first year after transplantation and every year until the fifth year. Secondary Objectives: 1. Pharmacokinetic study of immunosuppressive drugs (Tacrolimus, Everolimus and Mycophenolate Sodium) in the study population at days 7, 30, 60, 67, 90 and 180 post-transplant. 2. Serious adverse events (as internationally defined by ICH-GCP) every year, for five years. 3. Biopsy proven acute rejection rated every year, for five years. 4. Identify which of the renal filtration markers existing today, Cystatin C or Serum Creatinine, is more adequate to monitor renal function in elderly transplant and to develop abbreviated equations for eGFR from day 7 on. 5. Evaluation of other metabolic effects (bone density at month 12 post-transplant; vitamin D at months 2 and 12 post-transplant; and gonadal function at months 1 and 12 post-transplant) and Quality of Life at months 1, 12, 18, 24, 36, 48 and 60 post-transplant in the study population. 6. Left Ventricular Mass (LVM) and Left Ventricle Ejection Fraction (LVEF) measured by echocardiography at the end of the first year.
Interventions
DRUGEverolimus
This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC. Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml. Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter. Corticosteroids: as clinical practice.
Sponsors
University of Sao Paulo General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All renal (only) male and female recipients aged ≥ 60, years undergoing kidney transplantation from a living or deceased donor, including Expanded Criteria Donors (ECD). * Panel Reactive Antibody (PRA) \< 30%. * Patients who consented to participate in the study by signing the informed consent form before the transplant surgery to the 1st post-operative day).
Exclusion criteria
* Allergy to any of proposed medications * Patients with any active infection including HBV, HCV and HIV.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of functional graft | The study is planned to analyze all patients at the end of the fifth year after transplantation. However, an interim analysis will be done at the end of each year. | Composite efficacy failure demonstrated by graft loss and/or death with functional graft and/or GFR (Glomerular Filtration Rate determined by EDTA-Cr51) \< 50 ml/min at the end of first year after transplantation and every year until the fifth year. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Left Ventricle Ejection Fraction (LVEF) | Month: 12. | Left Ventricle Ejection Fraction (LVEF) measured by echocardiography at the end of the first year. |
| Pharmacokinetic of Everolimus | Days: 7, 30, 60, 67, 90, 180. | Pharmacokinetic of Everolimus in the study population at days 7, 30, 60, 67, 90 and 180 post-transplant. |
| Pharmacokinetic of Mycophenolate Sodium | Days: 7, 30, 60, 67, 90, 180. | Pharmacokinetic of Mycophenolate Sodium in the study population at days 7, 30, 60, 67, 90 and 180 post-transplant. |
| Pharmacokinetic of Tacrolimus | Days: 7, 30, 60, 67, 90, 180. | Pharmacokinetic of Tacrolimus in the study population at days 7, 30, 60, 67, 90 and 180 post-transplant. |
| Serious adverse events | Every year, for five years | Evaluate serious adverse events (as internationally defined by ICH-GCP). |
| Left Ventricular Mass (LVM) | Month: 12. | Left Ventricular Mass (LVM) measured by echocardiography at the end of the first year. |
| Renal filtration markers | Days: 7, 30, 37, 60, 67, 90, 180. Months: 12, 18, 24, 36, 48, 60 | Identify which of the renal filtration markers existing today, Cystatin C or Serum Creatinine, is more adequate to monitor renal function in elderly transplant and to develop abbreviated equations for eGFR from day 7 on. |
| Bone density | Month 12 | Evaluation of bone density at month 12 post-transplant. |
| Vitamin D | Months: 2, 12. | Evaluation of vitamin D at months 2 and 12 post-transplant. |
| Gonadal function | Months: 1, 12. | Evaluation of gonadal function at months 1 and 12 post-transplant. |
| Quality of Life | Months: 1, 12, 18, 24, 36, 48, 60. | Evaluate Quality of Life at months 1, 12, 18, 24, 36, 48 and 60 post-transplant in the study population. |
| Biopsy | Every year, for five years | Biopsy proven acute rejection rated every year, for five years. |
Countries
Brazil
Contacts
Primary ContactElias David-Neto, PhD
Outcome results
None listed